• Masimo Corporation has already presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and released preliminary fourth-quarter and full-year 2025 results indicating approximately 12% quarterly and 9% annual revenue growth.
• Management also highlighted a record level of incremental contract value from new and expanded hospital agreements, underscoring the importance of long-term customer relationships to the business.
• We’ll now examine how the record incremental contract value from new hospital agreements could influence Masimo’s existing investment narrative and outlook.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Masimo Investment Narrative Recap

To own Masimo, you need to believe its hospital monitoring franchise and newer adjacent markets can translate contract wins into durable, profitable growth. The preliminary 2025 results and record incremental contract value support the near term revenue story, but they also highlight the biggest risk right now: execution and timing around large, lumpy hospital agreements that still drive a significant share of the business. Overall, this news reinforces rather than materially changes that central tension.

The most connected recent development is Masimo’s expanded multi year partnership with Royal Philips, which integrates its monitoring technology and AI capabilities into Philips devices. Together with record new and expanded hospital contracts, this alignment with a major OEM speaks directly to the key catalyst of gaining share in high growth categories like advanced monitoring and capnography, while also amplifying the risk that any shift in partner priorities or competitive offerings could affect Masimo’s ability to convert innovation into sustained revenue.

Yet behind the contract momentum, investors should also be aware of the growing risk that customer consolidation and pricing pressure could...

Masimo's narrative projects $1.8 billion revenue and $293.5 million earnings by 2028. This requires a 5.1% yearly revenue decline and a $563.2 million earnings increase from -$269.7 million today.

Uncover how Masimo's forecasts yield a $183.12 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently see Masimo’s fair value between US$97.81 and US$183.13, reflecting very different expectations about upside. Against that backdrop, the renewed focus on large, lumpy hospital contracts and OEM relationships could meaningfully shape how reliably Masimo converts its technology strengths into future revenue streams, so it is worth exploring several of these views in more detail.

Explore 4 other fair value estimates on Masimo - why the stock might be worth as much as 41% more than the current price!

Build Your Own Masimo Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Masimo research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Masimo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Masimo's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.